Examkin

Soru

Zorluk: OrtaPreventive Care and Screening

A 48-year-old woman presents to the clinic for a health maintenance visit. She has a history of type 2 diabetes mellitus, moderate persistent asthma, and obesity. She smoked 1 pack of cigarettes daily for 22 years but quit 5 years ago. She currently feels well and has no acute complaints. Her medications include metformin, atorvastatin, a fluticasone-salmeterol inhaler, and a levonorgestrel-releasing intrauterine device.

A review of her preventive care history reveals the following:
- Screening mammography: Performed 1 year ago (normal, BI-RADS 1)
- Screening colonoscopy: Performed 3 years ago at age 45 (normal)
- Papanicolaou (Pap) test with human papillomavirus (HPV) co-testing: Performed 3 years ago at age 45 (negative)
- Hepatitis C virus antibody test: Performed 2 years ago (negative)
- Tetanus, diphtheria, and pertussis (Tdap) vaccine: Administered 3 years ago
- Influenza vaccine: Received an inactivated influenza vaccine 2 weeks ago

The patient has never received a pneumococcal or zoster vaccine.

Which of the following is the most appropriate next step in preventive care for this patient?

  1. A
    Dual-energy x-ray absorptiometry
  2. B
    Fecal immunochemical testing
  3. C
    Low-dose chest computed tomography
  4. D
    Recombinant zoster vaccine
  5. 20-valent pneumococcal conjugate vaccineCevap

Cevap

Administer the 20-valent pneumococcal conjugate vaccine.
The correct intervention is the administration of the 20-valent pneumococcal conjugate vaccine (PCV20). The Advisory Committee on Immunization Practices (ACIP) recommends pneumococcal vaccination for all adults aged 65 and older, as well as for adults aged 19 to 64 years who have certain underlying medical conditions. These conditions include diabetes mellitus, chronic lung disease (such as asthma), chronic heart disease, alcoholism, and immunocompromising conditions. Because this patient is 48 years old and has both diabetes mellitus and asthma, she is at increased risk for invasive pneumococcal disease. She should receive either a single dose of PCV20 or a dose of PCV15 followed by PPSV23. Since she has never received a pneumococcal vaccine, administering PCV20 today is the most appropriate next step.

Adım Adım Çözüm

1
Analyze the patient's age and underlying comorbidities.
The patient is 48 years old with type 2 diabetes mellitus and moderate persistent asthma.
Age and specific chronic diseases dictate vaccine and screening eligibility according to ACIP and USPSTF guidelines.
2
Evaluate the patient's eligibility for adult vaccinations.
She is eligible for pneumococcal vaccination due to her diabetes and asthma, but not eligible for the zoster vaccine due to her age (<50) and lack of severe immunocompromise.
ACIP recommends pneumococcal vaccination for all adults aged 19-64 with specific risk factors.
3
Review the patient's eligibility for cancer and osteoporosis screening.
She is up-to-date on breast, cervical, and colorectal cancer screening. She is too young for low-dose chest CT (starts at 50) and DEXA (starts at 65 without high risk).
Verifying exact age and interval cutoffs prevents ordering unnecessary tests or imaging.

Anahtar Kavram

Pneumococcal vaccination is indicated for adults aged 19 to 64 years who have specific underlying medical conditions, including diabetes mellitus, chronic lung disease (e.g., asthma, COPD), chronic heart disease, and chronic liver disease.
Bu soruyu puanla

Konular

Preventive Care and Screening

Bu konudan daha fazla soru